  Over the course of the last 2 decades our knowledge of autoimmune pancreatitis<disease> has increased exponentially. In this review , we summarize the clinical presentation , diagnosis and treatment of AIP , to better allow general gastroenterologists and primary care providers to consider AIP as a as a rare but important cause of painless obstructive jaundice and recurrent acute pancreatitis<disease> While steroids remain the mainstay of first line therapy , a number of patients with type 1 AIP require immunomodulators or rituximab to maintain remission; recommendations on the management of relapses continue to evolve.